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EDITORIAL REVIEW
Complement and the direct mediation of immune glomerular
injury: A new perspective
Although the complement system and the nephrotoxicity of
heterologous anti-kidney antisera were both described around
1900 [1, 2], complement and renal disease were not associated
for another half century. Glomerular immunoglobulin deposi-
tion as a cause for glomerulonephritis was demonstrated first in
experimental anti-kidney (nephrotoxic or anti-GBM) nephritis
[3, 4] and then in humans [5] in the mid-1950's. Burkholder then
showed that glomerular immune deposits activated heterolog-
ous complement in vitro [6]. The deposition of host complement
in vivo was demonstrated shortly thereafter [7, 8]. The concept
that complement was a mediator of kidney injury then derived
from observations that nephrotoxic antibodies altered to pre-
vent complement fixation were markedly less nephrotoxic [9]
and that complement depletion by various mechanisms greatly
ameliorated experimental anti-GBM nephritis [10—12].
Complement was initially thought to produce glomerular
injury directly through cytotoxic mechanisms since comple-
ment could lyse antibody-coated erythrocytes and other cells
[6]. However, in the Arthus reaction induced by immune
complex formation in dermal capillaries, complement activation
was accompanied by a marked neutrophil infiltrate which could
be eliminated by depletion of both neutrophils [13] and comple-
ment [14]. In anti-GBM nephritis complement fixation,
neutrophil infiltration and proteinuria could also be abolished in
most models by either complement or neutrophil depletion
[10—12]. These phenomena were not well explained by any
direct or lytic effect of complement. However, biologically
active complement activation products had now been identified,
including the potent neutrophil chemotactic factor C5a [14, 15].
Thus, by the 1970's the concept became established that the
role of complement in glomerulonephritis was an indirect one
which linked antibody deposits, via chemotactic and immune
adherence mechanisms, to neutrophils which produced glomer-
ular injury by the release of proteolytic enzymes [16—18]. There
were rare reservations. Hunsicker, in 1975, noted, "It is hard to
know what significance to attach to the very heavy epimembra-
nous deposition of C3 seen typically in membranous glomerulo-
nephritis, in which there is neither neutrophil infiltration nor
reaction of the endothelial or mesangial cells. So, while there
are evidences of complement-neutrophil induced damage in
some forms of glomerulonephritis, it is clearly not the only
mechanism for glomerular damage, and perhaps not the pre-
dominant one in human disease" [19]. However, the comple-
ment-neutrophil mechanism is the only one discussed in current
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reviews of the role of complement in the mediation of glomer-
ulonephritis [20-22].
It is our purpose to review recent experimental studies which
demonstrate that complement, through the terminal C5b-9
components, is a direct mediator of glomerular injury indepen-
dent of inflammatory cells, that this direct effect of complement
may be exclusively responsible for some types of glomerulone-
phritis such as membranous nephropathy, and that it plays a
role, along with the complement-neutrophil mechanism, in the
pathogenesis of other lesions. Evidence that this direct comple-
ment effect may be operative in human renal disease will also be
summarized and the possible mechanisms involved reviewed.
Mechanisms and biological consequences of
complement activation
Activation of the complement system as it relates to renal
disease is illustrated schematically in Figure 1 and reviewed
extensively elsewhere [20—24]. Activation by either the classical
or alternative complement pathway leads to formation of the
membrane attack complex (MAC) [20, 24] (Fig. 1). Classical
pathway activation is initiated by the Clq component of Cl
which binds with high affinity to the Fc region of immunoglob-
ulins including human IgG1, IgG2, IgG3 or 1gM [25, 261. When
bound to fixed tissue antigens, IgG antibodies must be in
appropriate spatial orientation as well as possess Fc portions
capable of Clq binding to activate complement [27, 28]. Im-
mune complexes containing more than 2 to 3 IgG molecules
initiate classical pathway activation both in the circulation and
in tissue deposits [29]. Clq binding is followed by internal
activation of Cir and Cis to produce enzymatically active
Clqrs which cleaves C4 and C2 to generate the biomolecular
C4b2a complex, the classical pathway C3 convertase, which
then cleaves C3 to C3a and C3b [30—32]. C3b binding to this
enzyme produces C4b2a3b, a new enzyme that cleaves CS to
C5a and C5b [33].
If immune deposits are physically accessible to circulating
neutrophils or macrophages bearing C3b (CR1) receptors, C3b
on the deposits provides a ligand for immune adherence [34].
Renal diseases characterized by low serum levels of Clq and
C4, and glomerular deposits of these complement components,
such as lupus nephritis and type I membranoproliferative gb-
merubonephritis, are presumed to be mediated in part by
complement activation through the classical pathway [20—22,
35, 36].
The alternative complement pathway can be activated non-
immunologically by a variety of activator substances including
polysaccharides, bacteria, a heat-labile serum factor in some
patients with nephritis, damaged renal tissue, and others
[20—22, 37, 38], as well as by IgA and IgE [23, 241. Alternative
pathway activation requires C3b which is generated randomly
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from C3 cleavage by normally present C3 cleaving enzymes
(C3b tick over) or by a C3b-like molecule formed from water-
hydrolyzed C3 (C3H20) [39, 40]. The C3H20 pathway is not
shown in Figure 1. When C3b binds to non-activator surfaces,
it is rapidly inactivated by the regulatory protein factor H(/31H)
which allows cleavage of C3b by factor I (C3b inactivator) to
form inactive C3bi (not shown in Fig. 1) [41,42]. However, C3b
bound to alternative pathway activator surfaces has fewer high
affinity factor H binding sites thus favoring the binding of factor
B [43] which is then cleaved by factor D to form the alternative
pathway C3 convertase, C3bBb [44]. C3bBb greatly increases
C3 cleavage and thereby C3b generation through the C3b
amplification loop (Fig. 1).
The role of complement in mediating immune reactions has
frequently been documented by inducing complement depletion
with cobra venom factor (CVF). CVF is an analog of mamma-
lian C3c which binds to factor B and is cleaved by factor D to
form a C3 convertase (CVFBb) that cannot be regulated by
factors H and I and therefore allows Ciactivation to proceed to
exhaustion [45]. The normal alternative pathway C3 convertase
is stabilized by properdin, a normal plasma protein [46], and by
C3 nephritic factor (C3 Net), an IgG antibody to neoantigens on
the C3bBb convertase present in some patients with type II
membranoproliferative glomerulonephritis and/or partial
lipodystrophy [47, 48]. C3 convertase stabilization favors C3b
generation [46]. A similar antibody to the classical pathway C3
convertase has also been reported [49]. As with the classical
pathway C3 convertase (C4b2a), the binding of additional C3b
to C3bBb converts the enzyme to a CS convertase (C3b(fl)BbP)
which cleaves CS to C5a and C5b [50]. Generation of C5b
through either pathway initiates self-assembly of the C5b-9
MAC.
Based on finding reduced serum levels of C3 but not Cl and
C4, and glomerular deposition of alternative pathway compo-
nents including properdin, factor H and factor B, renal diseases
such as acute post-streptococcal glomerulonephritis and type II
membranoproliferative glomerulonephritis are believed to in-
volve alternative pathway activation [20—22, 35, 51].
The biology and biochemistry of MAC formation have been
discussed in depth in recent reviews [52, 53]. MAC assembly
occurs when complement activation by either the classical or
alternative pathways results in C5 cleavage to produce C5b.
Nascent C5b interacts with C6 forming a stable C5b6 complex
which upon binding of C7 produces a trimolecular C5b-7
complex [52—54]. MAC formation cannot take place in the
absence of C6. The C5b6-7 complex can bind to lipid bilayer
membranes, and the adsorption of C8 produces tetramolecular
C5b-8 which is lytic for red cells, but at a much slower rate than
the complete MAC [52, 53, 55]. Addition and polymerization of
multiple C9 (poly C9) completes assembly of the MAC with
generation of higher affinity phospholipid binding sites [56]. A
hydrophobic tubule 160 A in length by 100 A in width is formed
which inserts about 50 to 100 A into the outer phospholipid
bilayer of cell membranes [52, 531. By electron microscopy, a
circular doughnut-like structure with a 200 A diameter electron
lucent rim and a 100 A electron opaque center is seen [52, 53].
The insertion of the MAC into cell membranes creates func-
tional pores in the membranes. The osmotic cell lysis that
follows appears to result from formation of aqueous channels
through the MAC [52, 53]. However, MAC perturbation of cell
membranes can also stimulate intracellular events that may
contribute to tissue injury without cell lysis (see below).
Non-mediator roles of complement and renal disease
Our purpose is to focus on the role of terminal complement in
the mediation of glomerular disease. However, complement
also has a variety of non-mediator effects which may be
important in the pathogenesis of renal disease and deserve
mention, but are beyond the scope of this review. Thus,
complement is important as an opsonin in host defense against
various foreign agents, and complement deficiencies have been
implicated in predisposing to chronic immune complex
nephritis [57]. Various complement fragments, particularly
C3b, appear to have significant effects on regulation of the
immune response and can modulate both humoral and cellular
responses to antigens and lymphokine production [58]. Com-
plement activation by immune complexes in the circulation may
inhibit lattice formation and thereby decrease immune complex
size [22, 59]. In primates, clearance of certain types of comple-
ment-fixing immune complexes may be influenced by C3b
receptors on erythrocytes with consequent effects on tissue
deposition [60, 61], although complement does not appear to
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Fig. 1. Schematic depiction of the sequence of
complement activation by the classical and
alternative pathways to form the membrane attack
complex (MAC).
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markedly alter circulating immune complex clearance in other
species [29]. The most important biologically active peptides
generated by complement activation are C3a and C5a,
anaphylatoxins which can cause histamine release, contract
smooth muscle, and increase capillary permeability [20—22].
Both are also small (MW 9 to 11,000 daltons), cationic mole-
cules which may alter glomerular permeability and enhance
deposition of immune complexes as reported with other small
polycations [621. Complement activation, primarily by the
alternative pathway, can solubilize immune complexes formed
in vitro and may contribute to in vivo modification of glomer-
ular immune complex deposits [22, 63]. Thus complement
depletion may delay removal of glomerular immune complex
deposits in acute serum sickness [64], and impaired complex
solubiization has been reported in sera from patients with
several forms of glomerulonephritis [65].
Complement and the mediation of glomerulonephritis
Complement-neutrophil mediated glomerular injury. Com-
plement participation in neutrophil-mediated glomerular injury
is extensively reviewed elsewhere [16, 18, 20—22, 27—29, 66],
does not involve C5b-9, and will only be summarized here.
Following anti-GBM antibody deposition, a prominent
neutrophil infiltrate is seen in glomeruli within 15 to 30 mm and
is maximal at about 2—1/2 to 4 hr [12, 67] coinciding with the
onset of non-selective proteinuria [68]. Protemuria is propor-
tional to the number of neutrophils in glomeruli [12] and can be
essentially abolished by neutrophil depletion [12, 69, 70].
Degranulating neutrophils displace endothelial cells to abut
directly on denuded GBM [18, 61, 71] which exhibits increased
permeability to ultrastructural tracer molecules [68].
Neutrophil-derived proteolytic enzymes, capable of digesting
GBM in vitro, and GBM fragments appear in the urine during
this phase of anti-GBM nephritis [68, 69]. Normocomplemen-
temic but neutrophil-depleted rabbits injected with anti-GBM
antibody develop a mild proteinuria when reconstituted with
neutrophils [70]. Recent studies confirm a reduction in protein-
uria following neutrophil depletion in both the heterologous and
autologous phases of anti-GBM nephritis and in other models
[72, 73].
Evidence that neutrophil participation in glomerular injury is
a consequence of complement activation rather than immune
adherence via Fc receptors is indirect. Generalized complement
depletion abolishes the glomerular neutrophil infiltrate and can
greatly reduce proteinuria in complement-dependent glomeru-
lonephritis [12, 17]. Deposition of equivalent antibodies that
provide Fc sites but do not activate complement does not result
in neutrophil infiltrates or complement-dependent proteinuria
[10, 28]. Whether complement activation results in neutrophil
recruitment by chemotactic factors or by promoting C3b-
mediated immune adherence is unknown. C5a is a potent
chemoattractant, but its role in neutrophil-mediated glomerular
injury has not been directly tested in vivo. Although comple-
ment activation is generally required to induce neutrophil-
mediated tissue injury, neutrophil-mediated glomerulonephritis
without complement participation has been reported [74, 75].
The macrophage has also been implicated in mediating the
autologous phase of several anti-GBM nephritis models and
accelerated acute serum sickness [76, 77]. Although C5a is
chemotactic for macrophages [20—22], which possess CR! re-
ceptors, complement depletion [77] and studies using F(ab')2
fragments [78] suggest that complement plays little role. Rather
Fc immune adherence mechanisms or participation of sensi-
tized T cells are probably involved [79].
Direct cell-independent effect of complement in glomerular
disease. The first evidence for a direct effect of complement,
independent of neutrophils, in renal disease derived from stud-
ies of experimental membranous nephropathy. This unique
lesion characterized by granular IgG deposits exclusively in a
subepithelial distribution lacks inflammatory cell infiltrates, yet
is associated with a marked increase in capillary wall perme-
ability and proteinuria [80]. Although C3 deposition is usually
seen by IF [80], the remarkable lack of inflammatory cells in
membranous nephropathy suggested that the pathogenesis of
this lesion might resemble the complement-independent anti-
body effects on glomerular permeability demonstrated in some
models of nephrotoxic nephritis [16, 18, 28].
The experimental model which most resembles membranous
nephropathy in humans is Heymann nephritis, induced in rats
by active immunization with a proximal tubular brush border
antigen (FxlA) [8!]. Because about 6 to 8 weeks is required for
proteinuria to develop in immunized animals, complement
depletion studies analogous to those carried out in anti-GBM
nephritis have never been technically feasible. However, a
similar lesion can be induced more rapidly by the passive
administration of a heterologous antibody to Fx!A [82]. Van
Damme et al [83] and ourselves [84] have demonstrated that the
subepithelial immune deposits in the passive Heymann
nephritis (PHN) model form in situ as a consequence of
antibody binding to a fixed glomerular antigen rather than from
the passive glomerular trapping of pre-formed immune com-
plexes as previously believed [85]. The pathogenic antigen
appears to be a 330Kd glycoprotein (GP330) derived from the
glomerular epithelial cell which initiates local immune complex
formation along the epithelial cell membrane abutting on the
GBM [86]. The immune complex aggregates formed then prob-
ably undergo capping and are shed into the adjacent lamina rara
externa and slit pore regions to form discontinuous granular
deposits [87, 88].
Our studies of PHN demonstrate continued glomerular dep-
osition of antibody and rat C3 for 5 days after antibody injection
until IgG deposition exceeds a proteinuric threshold of about 50
g/2 kidneys, which causes a heterologous phase proteinuria
[89]. Despite this evidence of continuous complement activa-
tion, no cellular inifitrates are seen in glomeruli [89, 90]. Since
heterologous phase proteinuria in PHN develops in less than 5
days, the role of complement and inflammatory cells in the
mediation of experimental membranous nephropathy can be
studied in this model. Salant et al administered 125I-anti-Fx!A
IgG to control rats and rats complement depleted by the daily
administration of CVF to maintain C3 levels at <5% of normal
and found unexpectedly that complement depletion completely
prevented the development of proteinuria in PHN without
altering glomerular antibody deposits [90] (Fig. 2). Selective
neutrophil and generalized cell depletion did not reduce pro-
teinuria, confirming the complement-dependent but inflamma-
tory cell-independent nature of this mechanism (Fig. 2) [901.
These studies provided the first evidence for a direct cell-
independent effect of complement in the mediation of renal
disease. We speculated that the absence of inflammatory cells
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Fig. 3. Effect of C6 deficiency (C6D) on development of proteinuria in
the cationic BSA serum sickness model of membranous nephropathy in
rabbits. One week after beginning daily antigen injections, C6D rabbits
() have no proteinuria (right panel) despite glomerular deposition of
anti-BSA antibody (left panel) equivalent to that in normocomple-
mentemic controls (). (From [92]). Mean SEM, *,D < 0.01 vs.
control; ** p> 0.05 vs. control.
heparan-sulfate proteoglycan anionic sites within the capillary
wall [94]. Groggel et al found a marked reduction in proteinuria
1 to 2 weeks after beginning daily antigen injections in C6D
rabbits with chronic serum sickness compared to normocom-
plementic controls despite equivalent deposits of both BSA
antigen and host antibody in both groups [92] (Fig. 3). Deposi-
tion of MAC neoantigens was also demonstrable in control but
not in C6D rabbits using a monoclonal antibody to polymerized
human C9 (Falk R, personal communication). This study pro-
vided the first direct evidence that the CSb-9 portion of the
complement system mediates renal injury. Our findings have
since been confirmed in serum sickness induced in rabbits with
native BSA [95]. However, C6D rabbits with serum sickness
had significant proteinuria and some glomerular inflammatory
cell infiltrates, suggesting participation of chemotactic and
immune adherence mechanisms as well, probably activated by
some immune complex formation at mesangial and subendo-
thelial sites [92]. More recent studies have therefore again
utilized the PHN model of membranous nephropathy in rats in
which immune complex deposits are exclusively subepithelial
and cellular infiltrates are absent. Baker et al have utilized both
intact and F(ab')2 fragments of goat antibody to rat C6 to reduce
plasma levels of C6 hemolytic activity to < 5% of normal while
maintaining C3 antigenic activity above 80% for 4 days. As
shown in Figure 4, C6 depletion proved as effective as CVF in
totally preventing the development of proteinuria in PHN
despite deposition of nephritogenic quantities of antibody [96].
The participation of C5b-9 in glomerular disease is not
confined to membranous nephropathy. Groggel et al have
studied anti-GBM nephritis in C6D rabbits and controls and
demonstrated a marked reduction in heterologous phase pro-
teinuria in C6D rabbits despite more antibody deposition in the
C6D group [97] (Fig. 5). It is noteworthy that C6D rabbits also
had less impairment of renal function than controls despite
deposition of larger amounts of anti-GBM antibody [97]. The
reduction of GFR induced by anti-GBM antibody is known to
be complement-dependent, but has generally been attributed to
chemotactic or direct hemodynamic effects of CSa [98, 99].
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Fig. 2. Effects of complement depletion (ru) on renal antibody deposi-
tion (left panel), and of complement and neutrophil (02) depletion on
proteinuria (right panel) in the FHN model of membranous nephrop-
athy in rats. Controls are shown as D. Numbers in parentheses are
animals studied. Complement depletion abolished proteinuria at 5 days
without altering renal antibody deposits. In separate experiments,
neutrophil depletion had no effect on proteinuria demonstrating the
complement-dependent, neutrophil-independent nature of this lesion.
(From [90]). Mean SEM. *V < 0.01 vs. control; **> 0.05vs. control.
probably reflected interposition of the cell-impermeant GBM
between the sibepithelial site of deposit formation and the
circulation, thereby preventing immune adherence by inflam-
matory cells, and hydrodynamic filtration forces which would
prevent the diffusion of complement-derived chemotactic fac-
tors toward the capillary lumen. We concluded that the most
likely mechanism of capillary wall injury was membrane dam-
age induced by the formation of the C5b-9 MAC [90].
To determine whether this new neutrophil-independent
mechanism of complement-mediated glomerular injury was
restricted to the fixed epithelial cell antigen system, Adler et al
"planted" small amounts of non-complement fixing sheep
gamma 2 IgG antibody to epithelial cell antigen as an antigen in
a subepithelial distribution without causing measurable protein-
uria [91]. Then, to avoid IgG antigen in the circulation, kidneys
bearing planted antigen were transplanted into syngeneic recip-
ients, and injections of rat antibody to sheep IgG were given
one day later. The resulting in situ formation of subepithelial
IgG-anti-IgG immune complexes resulted in modest C3 deposi-
tion and heavy proteinuria. Again, development of proteinuria
was prevented by complement depletion with CVF, but was
unaltered by selectively depleting neutrophils or generalized
cell depletion.
To test the hypothesis derived from these studies that the
terminal CSb-9 portion of the complement cascade is patho-
genic in glomerular disease, we utilized rabbits genetically
deficient in the sixth component of complement (C6D) [92].
Previous studies have demonstrated normal chemotactic factor
generation and neutrophil function in these animals [93]. Rea-
soning that a role for C5b-9 in mediating glomerular injury was
most likely in a membranous lesion, chronic serum sickness
was induced by repeated injections of BSA chemically modified
to a p1 of about 9.5. This model is characterized by predomi-
nately subepithelial deposits apparently formed in situ following
charge interactions between the cationic BSA antigen and
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Fig. 4. Effect of C6 depletion on development ofproteinuria in the PHN
model of membranous nephropathy in rats. In the right panel, rats
depleted of C6 (m) failed to develop proteinuria at 4 days compared to
controls (rn). Despite the absence of proteinuria, in the left panel, the
glomerular deposition of 125-I antibody to glomerular epithelial cell
antigen is equivalent in the two groups. (From [96]). Mean SEM. J'
0.025 vs. control; P> 0.05 vs. control.
Thus, C5b-9 may affect the physiologic as well as permeability
characteristics of the glomerulus.
The studies reviewed above provide clear functional evi-
dence that C5b-9 participates directly in mediating glomerular
disease. Additional indirect evidence to support this hypothesis
has derived from several sources and is summarized in Tables 1
and 2. Koffler et al utilized an antibody to human C9 and MAC
to demonstrate MAC neoantigens in glomerular immune depos-
its in a rat model of serum sickness [100]. Immunoelectron
microscopic studies demonstrated MAC deposition concordant
with IgG, C3, and BSA in capillary wall deposits. However,
overlying membranes of effaced epithelial podocytes stained
intensely for MAC, less for C3, and were negative for IgG and
BSA [100]. Resistance of MAC neoantigens to elution with acid
buffers suggests they are inserted into glomerular structures and
not simply components of the immune complex lattice [52, 100].
MAC formation on the epithelial cell membrane may precede
cell detachment or possibly MACs formed at one site may
migrate to induce tissue damage to adjacent structures [loll.
We have utilized goat antibodies to human C5, C6, C7, and
C8, shown by neutralization studies to be cross-reactive with
rat complement components, and antibodies to neoantigens of
the rat MAC, to show deposition of rat terminal complement
components, and MAC neoantigens in immune deposits only in
models where glomerular injury is complement-dependent,
including the heterologous and autologous phases of PHN and
active Heymann nephntis [102, 1031, which we presume is
mediated by similar mechanisms [104] (Table 1). MAC deposits
have also been noted in Heymann nephritis by others and
correlated with the development of proteinuria [105, 1061. In
contrast, other models with equivalent proteinuria unaffected
by complement depletion do not have detectable deposits of
terminal complement components or MAC neoantigens [102,
1031 (Table 1). MAC deposits are also present with type IV
collagen and C3, but without immunoglobulin in areas of
mesangial sclerosis in chronic experimental glomerular disease
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Fig. 5. Effect of C6 deficiency on heterologous phase proteinuria in
nephrotoxic nephritis in rabbits. In the ri ght panel, C6-deficient animals() have a marked reduction in proteinuria compared to controls (n).
In the left panel, glomerular deposition of 125-I anti-GBM antibody is
equivalent in the two groups. (From [97]). Mean SEM. < 0.001 vs.
control; **P > 0.05 vs. control.
[107], a finding also noted in humans [1081. Taken in concert
with the functional studies reviewed above, these im-
munopathologic findings strongly suggest that terminal comple-
ment mechanisms are probably operative in several forms of
immune and perhaps non-immune experimental glomerular
disease.
Terminal complement and human renal disease
The role of C5b-9 in the mediation of human renal disease has
only been inferred from immunopathologic studies utilizing
antibodies to MAC neoantigens to demonstrate their presence
in glomeruli and other structures. These studies, therefore,
provide only indirect evidence for the nephrotoxicity of MACs
as mediators of tissue injury. Studies in humans are summa-
rized in Table 2. At least three patterns are emerging. Small
amounts of MAC deposits in the mesangium have been noted,
usually in the absence of immune deposits, in a wide variety of
lesions including minimal change nephrotic syndrome, crescen-
tic glomerulonephritis, scleroderma, myeloma, light chain dis-
ease, allergic interstitial nephritis, transplant rejection,
amyloid, diabetes, hereditary nephritis, and even normal kid-
neys [108—i 12]. Whether these deposits represent macromolec-
ular complexes trapped from the circulation [113] or local
complement activation by damaged renal structures is unclear,
although their apparent association with cell membrane frag-
ments [1121 and the capacity of damaged cells to activate
complement in vitro [37, 1141 suggest the latter. These deposits
are presumed to be non-pathogenic. However, since C5b-9 can
induce production of inflammatory mediators by mesangial cells
as discussed below, such deposits could have potentially harm-
ful effects.
MAC deposits have also been noted independent of immu-
noglobulin in several structural giomerular lesions such as
sclerosis, PAS-positive material, and fibrin caps in diabetic
glomeruli, areas of hyalinization in damaged vessels, along
Bowman's capsule and TBM in areas of interstitial inflamma-
tion, and in amyloid deposits [108, 112, 115] (Table 2). Damaged
cells have been implicated in the genesis of these deposits as
well [1121. These MAC deposits probably result from non-
Control C6D Control C6D
(6) 161 (6) (6)
884 Couser et a!
Table 1. C5b-9 Neoantigen deposition and complement-dependent proteinuria in experimental glomerular diseases
Complement-dependent
Experimental model proteinuria C5b-9 deposits Location
Passive Heymann
nephritis
heterologous phase Yes, C6 [90, 96) CS, C6, C7, C8, MAC [102, 103] Capillary wall
autologous phase (early) Yes [91] CS, C6, C7, C8, MAC [102, 103] Capillary wall
autologous phase (late) No [90] MAC [1071 Mesangium, sclerotic areas
Active Heymann nephritis Unknown CS, C6, C7, C8, C9, MAC [102, 103, Capillary wall, tubular epithelium
105, 1061
Chronic serum sickness
rabbits Yes, C6 [92, 95] Poly C9 [95] Capillary wall, humps
rats Unknown C9, MAC [100] Capillary wall, mesangium, epithelial cell
membranes, and TBM
Nephrotoxic nephritis
sheep anti-rat
heterologous phase No [102, 103] Negative [102, 1031 —
sheep anti-rabbit
heterologous phase Yes, C6 [97] Not done —
Aminonucleoside No [102, 103] Negative [102, 103] —
nephrosis
Table 2. Glomerular deposits of C5b-9 neoantigens in human renal disease
Disease C5b-9 deposits Location
Damaged tissue
Diabetes Poly C9, MAC [108, 112] TBM, Bowman's capsule, mesangium, nodules,
JG areas, hyalinized vessels, sclerosis
Hypertension Poly C9 [108]
Obstructive uropathy Poly C9 [108]
Congenital dysplasia Poly C9 [108]
Amyloid Poly C9, MAC [108, 112] Amyloid deposits
Lupus Poly C9, MAC [108, 112, 115] Thickened TMB, fibrinoid necrosis of vessels,
interstitial inflammation
Minor mesangial deposits
(With or without IgG and C3)
Normal kidneys CS, CS, C9, poly C9, MAC [108, 111, 112] Mesangium, media of distal cortical
Minimal change disease, MAC [110, 1121 Predominately mesangial stalk
Crescentic glomerulonephritis,
Scleroderma, myeloma
L chain disease, allergic
Interstitial nephritis,
Transplant rejection,
Alport's syndrome
Capillary wall and/or mesangial deposits
(With IgG, C3)
Membranous nephropathy C5, C6, CS, C9, MAC [108—110, 1121 Capillary wall, occasional mesangium
Anti-GBM nephritis MAC [109, 1101 Capillary wall
Lupus nephritis (II, III, IV, V) C9, MAC [108, 112, 115) Mesangium, capillary wall
IgA nephropathy C5, C6, CS, C9, poly C9,MAC [112, Predominantly mesangium
108—110]
Henoch-Schönlein purpura MAC [108, 110, 1121 Predominantly mesangium
Post-streptococcal nephritis CS, poly C9 [116] Capillary wall early, mesangium late
Membranoproliferative glomerulonephritis
Type I MAC, poly C9 [108, 110, 112] Mesangium and capillary wall
Type II Poly C9 [1081 Mesangium and capillary wall, TBMs
immune complement activation and may be secondary phenom-
ena rather than causative agents.
Of more interest are the findings of MAC neoantigens con-
cordant with immune deposits in a variety of glomerular dis-
eases, including all forms of lupus nephritis, idiopathic and
drug-induced membranous nephropathy, anti-GBM nephritis,
types I and II membranoproliferative glomerulonephritis, IgA
nephropathy, Henoch-SchOnlein purpura, and post-streptococ-
cal glomerulonephritis [108—i 12, 115, 1161 (Table 2). Although
deposits of MAC in the absence of immunoglobulins as noted
above may occur in these diseases as well, MAC neoantigens
are clearly associated with deposits of immunoglobulin and
usually C3 both along the capillary wall and in the mesangium.
In some cases, a relative absence of MAC deposits has been
associated with more deposition of complement control pro-
teins suggesting that these may modulate MAC formation in
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Fig. 6. Immunofluorescent staining for sheep IgG (left), rat C3 (middle), and rat CSb-9 neoantigens (right) in glomeruli of a rat with PHN 5 days
after injection of sheep antibody to glomerular epithelial cell antigen. Strong staining for sheep IgG and rat MAC is present in a subepithelial
distribution. Staining for C3 is similar in distribution but of less intensity. (x400)
glomeruli [1121. In these antibody-mediated glomerular lesions
it seems probable that terminal complement mechanisms do
play a nephntogenic role in mediating glomerular injury similar
to that demonstrated experimentally in the animal models
discussed above.
A compelling argument against this suggestion could be made
if typical antibody or immune complex-mediated glomerulone-
phritis developed in patients with genetic deficiencies in termi-
nal complement components. Terminal complement deficien-
cies have usually been associated with recurrent bacterial
infections and rarely with glomerulonephritis [57]. One patient
with CS deficiency had lupus nephritis and subepithelial im-
mune deposits but minimal proteinuria [117]. Reduced levels of
C6 have been described in some patients with type I
membranoproliferative glomerulonephritis but may be second-
ary [1181. Single patients with C7 deficiency and congenital
proteinuria, lupus with nephrotic syndrome, and pyelonephritis
with end-stage renal disease accompanied by proteinuna have
been reported, but renal histology was not described [119—121].
One patient with C8 deficiency and a lupus-like syndrome
associated with proteinuria and a poorly characterized glomer-
ular lesion has also been reported [122]. Thus, the minimal
literature available on terminal complement component defi-
ciencies in humans does not exclude an important role for C5b-9
in mediating glomerular disease.
Terminal complement in non-renal tissue injury
Although the only studies documenting the pathogenicity of a
terminal complement mechanism in tissue injury are those in
experimental glomerulonephritis reviewed above, the demon-
stration of MAC deposits and the capacity of other cells and
tissues to activate complement suggest that this mechanism
may be operative in a variety of non-renal lesions as well. In
lupus, MAC deposits are present in immune complexes at the
dermal-epidermal junction of involved skin but absent despite
similar immune deposits in uninvolved skin [123]. Experimental
myasthenia gravis induced with antibody to acetylcholine re-
ceptor protein can be prevented by complement depletion [124],
and C9 deposits (with IgG and C3) correlate with structural
damage to the post-synaptic membranes in humans [125]. Acute
lung injury induced by in situ formation of IgA antibody-antigen
complexes [126] and accelerated cardiac allogralt rejection in
the rat [127, 128] have both been shown to be complement-
dependent but neutrophil-independent processes of immune
tissue injury similar to experimental membranous nephropathy
and may involve terminal complement mechanisms.
Several forms of damaged tissue can activate complement
non-immunologically to form MACs. We have shown that
damaged kidney cells can form a membrane-bound C3
convertase and consume and bind C3 and terminal complement
components [37, 114]. This mechanism may account for the
deposits of MAC noted in association with cell fragments in the
mesangium and at other sites in the absence of immune deposits
[108—112].
Pathophysiology of terminal complement-induced
glomerular injury
Since the principal renal consequence of terminal comple-
ment component activation demonstrated experimentally is
proteinuria, CSb-9 must produce some perturbation of the
glomerular filtration barrier to macromolecules. The nature of
this barrier, which consists of endothelial cells with fenestrae of
about 44 nm, the GBM itself, and epithelial cell foot processes
with intervening slit diaphragms, has been extensively reviewed
elsewhere [129, 130]. Since the exact site of MAC localization
has not yet been well defined in either experimental models or
in humans, any discussion of the mechanism(s) of the C5b-9
effect must be speculative. With this reservation, however, we
believe that four possibilities merit consideration: an effect on
glomerular hemodynamics resulting in increased protein filtra-
tion on a physiologic basis, a non-lytic alteration in glomerular
extracellular matrix represented by GBM, lytic effects on
glomerular cells, and non-lytic effects on resident glomerular
cells resulting in alterated cell metabolism leading to abnormal
barrier function.
The transglomerular transport of macromolecules is gov-
erned primarily by their size, shape, and charge, but is also
influenced by hemodynamic factors [129, 130]. Glomerular
deposition of anti-GBM antibody results in a decrease in GFR
due to a fall in glomerular plasma flow and K!' accompanied by
an increase in the filtration fraction (GFRIRBF), a circumstance
which can lead to increased protein filtration by diffusion [129,
131]. Much of this reduction in GFR is known to be comple-
ment-dependent L98] and may be mediated by C5a [99]. How-
ever, C6D rabbits have less reduction in GFR than controls
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following anti-GBM antibody administration, raising the possi-
bility that C5b-9 may have hemodynamic effects that result in
an increase in antibody-induced protein filtration [97]. How-
ever, the magnitude of this effect is not likely to account for the
large differences observed between C6D and normal animals in
antibody-induced proteinuria [131, 132].
The GBM itself is the major barrier to protein filtration and is
composed of a fibrillar network of glycopeptide chains, includ-
ing a non-polar type IV collagen-like component, a more polar
non-collagen fraction, type V collagen, various proteoglycans,
laminin, and entactin [129, 1301. In addition, the heparan-sulfate
proteoglycans which are believed to account for much of the
negative charge barrier to the filtration of anionic proteins such
as albumin reside primarily within the lamina rara interna and
externa of the GBM [129]. However, the GBM contains no
cellular lipid bilayers, and there is little evidence that the MAC
can insert into and damage extracellular matrices. However,
Kopp and Burrell have demonstrated binding of C9 and forma-
tion of MAC-like structures on antibody-coated alveolar base-
ment membrane, a structure antigenically similar to GBM [133].
Moreover, Williams et al have shown that the epithelial surface
of cell-free human GBM can activate the alternate complement
pathway directly [134]. It is known that minor structural alter-
ations in the GBM, induced for example by binding of IgG
antibody alone, may markedly increase permeability to protein
in the absence of visible structural damage [66, 135]. Thus, the
possibility that MAC insertion or accumulation within GBM
could have a similar effect cannot be excluded.
However, the best established biologic effects of C5b-9 result
from its insertion into lipid bilayers of cell membranes, an event
which can induce cell lysis and death, or in other systems may
result in non-lethal perturbations in the cell membrane that
markedly but reversibly alter cell metabolism [136]. Although
the endothelial cell, because of its large fenestrae, is not
normally considered a major barrier to protein filtration [129,
130], antibody binding to antigens expressed on the endothelial
cell surface has been reported to induce proteinuria [137], and
endothelial cell disruption and separation from the GBM are
prominent ultrastructural features of most complement-depen-
dent forms of anti-GBM disease [11, 12, 16, 17, 67, 138]. The
possibility that anti-endothelial antibodies are present in prep-
arations of nephrotoxic serum has certainly not been carefully
excluded in most studies of anti-GBM nephritis.
The best established terminal complement effect producing
proteinuria results from antibody binding along the epithelial
cell membrane to form epimembranous immune complex de-
posits in situ in the Heymann nephritis models [91, 97, 102, 103,
105, 106]. Capping and shedding of immune complexes and
MACs with accumulation beneath the slit pore diaphragm [87,
88] could result in damage to that structure, which may be an
important component of the filtration barrier [129]. A cytotoxic
effect resulting in epithelial cell damage or death is also possible
with increased permeability resulting from loss of cell-surface
associated sialoglycoproteins or detachment of the cell itself
from the GBM as may occur in membranous lesions [100, 139,
140]. Since a terminal complement-dependent lesion also re-
sults when subepithelial deposits are formed from exogenous
antigens such as cationic BSA [92] a lytic effect on the epithelial
cell might also be exerted by immune complexes forming locally
in the lamina rara externa rather than on the cell membrane
itself. This possibility is suggested by the ultrastructural studies
of Koffler et al demonstrating prominent MAC deposits along
membranes of detached epithelial cells that are not contiguous
with deposits of IgG and BSA in more proximal portions of the
capillary wall [100]. However, ultrastructural studies of epithe-
hal cells associated with MAC deposits in man and in experi-
mental models do not suggest cell death [100, 112], although
minor structural abnormalities have been reported [112]. More-
over, it is clear that nucleated cells, unlike erythrocytes, are
quite resistant to the lytic effects of C5b-9 [141].
Finally, the capacity of C5b-9 to induce non-lethal perturba-
tions in cell membranes that alter intracellular metabolism and
induce release of inflammatory mediators is now well estab-
lished. CSb-9 stimulation of human platelets mediates increased
release of serotonin and thromboxane B2 via metabolism of
mobilized arachidonate [142]. Rat peritoneal macrophages re-
spond to C5b-9 membrane stimulation by releasing
phospholipids and arachidonic acid and by mobilizing lipid
metabolic pathways to convert the arachidonate to PGE2 and
thromboxane B2 [136]. Rat mesangial cells, which share a
number of macrophage characteristics, respond to stimulation
by non-lytic concentrations of C5b-9 by releasing large amounts
of vasodilatory prostaglandins and a cellular proliferation pro-
moting growth factor closely resembling interleukin I [143]. We
have demonstrated that rat mesangial cells also produce reac-
tive oxygen species on stimulation with sublethal quantities of
C5b-9 [144]. Endothelial cells have recently been reported to
produce reactive oxygen species as well [1451. Reactive oxygen
species generated by activated neutrophils have been shown to
cause proteinuria in some models [73]. Although it seems
unlikely that non-lytic effects of C5b-9 on mesangial cells alone
can account for the marked changes in capillary wall function in
membranous nephropathy, non-lytic effects of CSb-9 on
glomerular epithelial or endothelial cells that might result in
proteinuria have not yet been studied. Aminonucleoside of
puromycin, for example, induces reversible proteinuria by
altering epithelial cell metabolism in a way which remains
poorly understood [146, 147]. The suggestion that glomeruli of
rabbits with C6-dependent serum sickness may produce a
qualitatively abnormal heparan sulfate of reduced negative
charge could reflect a C5b-9-induced abnormality in epithelial
cell function that might contribute to proteinuria [148]. Thus, it
now seems likely that cell membrane perturbation by CSb-9
may initiate activation of phospholipases, transmethylases, and
other metabolic processes that induce local release of several
potential inflammatory mediators and may cause alterations in
cell metabolism, resulting in abnormal production of basement
membrane components critical to maintenance of the glomeru-
lar ifitration barrier. Obviously, much more work is required to
determine the full range of effects of terminal complement on
the biologic activities of the resident glomerular cell population,
as well as to define which of these various processes demon-
strated in vitro contributes in any meaningful way to the now
well-established nephritogenic effect of terminal complement
on the glomerulus.
Concluding remarks
The importance of the complement system in mediating
glomerular disease has been confirmed in recent studies. How-
ever, these studies implicate the C5b-9 portion of the comple-
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ment system rather than neutrophil-mediated inflammation as a
major effector mechanism. A direct functional effect of C5b-9
on glomerular permeability has now been clearly established in
several models of both in situ immune complex nephritis and in
anti-GBM nephritis. The presence of C5b-9 neoantigens in
immune deposits and at other sites in a variety of human renal
diseases suggests that this mechanism may be pathogenic in
man as well. The molecular basis for this direct complement
effect is unclear. Hemodynamic factors or lytic effects on
glomerular cells or extracellular matrices cannot yet be ex-
cluded. However, non-lethal effects of C5b-9, activated by
immune or non-immune mechanisms, on the metabolism of
resident glomerular cells stimulating the release of mediators
which damage the filtration barrier or altering the synthesis of
capillary wall components seem more probable explanations for
this new mechanism of glomerular injury.
WILLIAM G. COUSER
PATRICIA J. BAKER
STEPHEN ADLER
Seattle, Washington, USA
Notes added in proof
Using an isolated perfused kidney system, Cybulski et al recently
demonstrated that C8 is required for mediation of proteinuria in the
PHN model (Abstracts of the American Society of Nephrology, 1985).
Hänsch et al have recently demonstrated production of prostaglandins
and thromboxane by rat glomerular epithelial cells in response to C5b-9
(Abstracts of the American Society of Nephrology, 1985).
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